{"id":457418,"date":"2021-03-15T08:03:20","date_gmt":"2021-03-15T12:03:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=457418"},"modified":"2021-03-15T08:03:20","modified_gmt":"2021-03-15T12:03:20","slug":"cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/","title":{"rendered":"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., March  15, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HyzRTs6ls-ZHPU4pLliGk9pj9-ld9uDcPHNXwNih6bjF22PEPIl9eyCqFeX9d7yQt0mUNs-nxfVWNdR1Tq_2smZ8hbwrBZuOH8XXBzsJkMM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Cue Biopharma, Inc.<\/a> (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021.<\/p>\n<p>Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, the lead Immuno-STAT\u2122 <em>(Selective Targeting and Alteration of T cells)<\/em> platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent\/metastatic head and neck cancer. The presentation will also focus on the Company\u2019s platform developments and pipeline progress including the CUE-400 series, a novel class of therapeutic molecules for broad applications in multiple autoimmune diseases.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\">\n            <strong>Presentation Details<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\">\n            <strong>Oppenheimer 31st Annual Healthcare Conference<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%\">\n            <strong>Date and Time:<\/strong>\n          <\/td>\n<td style=\"max-width:90%;width:90%;min-width:90%\">Thursday, March 18, 2021 at 9:20 a.m. EDT<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Webcast link:<\/strong>\n          <\/td>\n<td>\n            <a href=\"https:\/\/protect-us.mimecast.com\/s\/cgvmCJ6jvXfB7roUVhCBF\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>https:\/\/wsw.com\/webcast\/oppenheimer9\/cue\/2481281<\/u><br \/>\n            <\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>A live and archived webcast of the presentation will be available in the Investors and Media section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x282FX2rJkQQIjo6YPDHFkXT9MjPQ7kDI3M5rKkvRZbU9Od_KmgVpxIG-6QG4Y-SbwBnjxE-cerDfCpzXbhRBW6Q9_NpGw5Opqo1tnn64qk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cuebiopharma.com<\/a>. The webcast will be archived for 30 days.<\/p>\n<p>\n        <strong>About\u00a0Cue Biopharma<\/strong><br \/>\n        <br \/>Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient\u2019s body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company\u2019s proprietary platform, Immuno-STAT\u2122 <em>(Selective Targeting and Alteration of T cells)<\/em> is designed to harness the body\u2019s intrinsic immune system without the need for ex vivo manipulation.<\/p>\n<p>Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.<\/p>\n<p>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x282FX2rJkQQIjo6YPDHFnmwvjspySdKSuGe_cPeJYQ4Z1SGSrZ7FV0mLLR4a0fBuk-BC4iheKg9aA0CHo2jsR0BHe4lJ3CA41uTJfF2PZg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cuebiopharma.com<\/a>\u00a0and follow us on Twitter <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MZLDW8bsT8OqZdjQCxp289NtTrS5UEXHZUxX1GgYJAFcpsVNJnUj3zQIEtPx41gisQv3JwNQzsmj00BtwnAIebWzdQt20AWt5I90lbFpl1mHyFqDdf7iUomS92j0ufxz\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/twitter.com\/CueBiopharma<\/a>.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>George B. Zavoico, Ph.D.<br \/>VP, Investor Relations &amp; Corporate Development <br \/>Cue Biopharma, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Nf6Nb64HeNxlvYe3f3ISDSMAFIxlvy9r3jpxnj4BpHcdyzZnFfJrfuoOD3Fr53MpmjDA5yPgKnfw2G9D2gf1SNOtye7VqNxH0ff-uADQgds=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">gzavoico@cuebio.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Darren Opland, Ph.D.<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b47_BDXHwdsTGrpyu751MYKvCjYzoW0y9BMXVjKbpqu6f7x1o2DUWaMwBxb6lj842iWR_CuXvgHvdGRLV1fWqOwukmxD5k6fpA6zQRQsBr4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">darren@lifescicomms.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d65f4637-a517-4b1e-90ba-5ba2d8d07ce3\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021. Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, the lead Immuno-STAT\u2122 (Selective Targeting and Alteration of T cells) platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent\/metastatic head and neck cancer. The presentation will also focus on the Company\u2019s platform developments and pipeline progress including the CUE-400 series, a novel class of therapeutic molecules for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-457418","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021. Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, the lead Immuno-STAT\u2122 (Selective Targeting and Alteration of T cells) platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent\/metastatic head and neck cancer. The presentation will also focus on the Company\u2019s platform developments and pipeline progress including the CUE-400 series, a novel class of therapeutic molecules for &hellip; Continue reading &quot;Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-15T12:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference\",\"datePublished\":\"2021-03-15T12:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/\"},\"wordCount\":350,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/\",\"name\":\"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=\",\"datePublished\":\"2021-03-15T12:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","og_description":"CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) &#8212; Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient\u2019s body, announced today that it will present at the virtual Oppenheimer 31st Annual Healthcare Conference being held March 16-18, 2021. Cue Biopharma will provide a corporate update highlighting clinical progress with CUE-101, the lead Immuno-STAT\u2122 (Selective Targeting and Alteration of T cells) platform-based therapeutic, in clinical trials for the treatment of patients with HPV+ recurrent\/metastatic head and neck cancer. The presentation will also focus on the Company\u2019s platform developments and pipeline progress including the CUE-400 series, a novel class of therapeutic molecules for &hellip; Continue reading \"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-15T12:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference","datePublished":"2021-03-15T12:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/"},"wordCount":350,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/","name":"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=","datePublished":"2021-03-15T12:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4OTY4MiM0MDYzMDMwIzIwOTI2OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cue-biopharma-to-present-corporate-overview-and-clinical-progress-at-the-upcoming-oppenheimer-31st-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cue Biopharma to Present Corporate Overview and Clinical Progress at the Upcoming Oppenheimer 31st Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=457418"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/457418\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=457418"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=457418"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=457418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}